Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. (PHAT) Revenue
Annual & quarterly revenue history · segment & region breakdown
PHAT · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsPhathom Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.20B, an increase of 216.93% year-over-year from $0.18B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.18B | +$0.12B | +216.93% |
| 2024-12-31 | $0.06B | +$0.05B | +8001.47% |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare PHAT revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Phathom Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Phathom Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Phathom Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PHAT revenue · 4 questionsPHAT's trailing twelve-month (TTM) revenue is $0.20B. That is an increase of 216.93% year-over-year from $0.18B in FY2025.
▸ Source: FMP · Phathom Pharmaceuticals, Inc. SEC filings · GAAP · Phathom Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026